Balyasny Asset Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $801K | Sell |
9,998
-1,564,393
| -99% | -$129M | ﹤0.01% | 2166 |
|
|
2025
Q4 | $134M | Buy |
1,574,391
+503,931
| +47% | +$41.4M | 0.17% | 127 |
|
|
2025
Q3 | $83.2M | Sell |
1,070,460
-416,442
| -28% | -$32.5M | 0.11% | 212 |
|
|
2025
Q2 | $116M | Sell |
1,486,902
-637,531
| -30% | -$47.5M | 0.18% | 124 |
|
|
2025
Q1 | $154M | Buy |
2,124,433
+729,255
| +52% | +$52.2M | 0.25% | 68 |
|
|
2024
Q4 | $103M | Buy |
1,395,178
+675,651
| +94% | +$47.3M | 0.15% | 144 |
|
|
2024
Q3 | $47.5M | Sell |
719,527
-297,471
| -29% | -$21.6M | 0.08% | 323 |
|
|
2024
Q2 | $93.9M | Buy |
1,016,998
+159,291
| +19% | +$14.1M | 0.16% | 137 |
|
|
2024
Q1 | $82M | Buy |
857,707
+761,969
| +796% | +$64M | 0.14% | 165 |
|
|
2023
Q4 | $7.3M | Buy |
95,738
+88,577
| +1,237% | +$6.16M | 0.01% | 979 |
|
|
2023
Q3 | $496K | Sell |
7,161
-391,177
| -98% | -$31.4M | ﹤0.01% | 1763 |
|
|
2023
Q2 | $37.6M | Sell |
398,338
-761,581
| -66% | -$66.2M | 0.08% | 328 |
|
|
2023
Q1 | $96M | Buy |
1,159,919
+24,640
| +2% | +$1.94M | 0.24% | 92 |
|
|
2022
Q4 | $84.7M | Buy |
+1,135,279
| New | +$87.5M | 0.23% | 93 |
|
|
2021
Q3 | – | Sell |
-645,026
| Closed | -$66.8M | – | 2080 |
|
|
2021
Q2 | $66.8M | Buy |
+645,026
| New | +$60.8M | 0.32% | 57 |
|
|
2020
Q2 | – | Sell |
-142,812
| Closed | -$8.98M | – | 1236 |
|
|
2020
Q1 | $8.98M | Buy |
142,812
+10,005
| +8% | +$722K | 0.11% | 259 |
|
|
2019
Q4 | $10.3M | Sell |
132,807
-152,613
| -53% | -$11.9M | 0.06% | 417 |
|
|
2019
Q3 | $20.9M | Buy |
285,420
+243,654
| +583% | +$17.1M | 0.14% | 237 |
|
|
2019
Q2 | $2.57M | Buy |
+41,766
| New | +$2.53M | 0.02% | 803 |
|
|
2018
Q1 | – | Sell |
-457,659
| Closed | -$17.2M | – | 2040 |
|
|
2017
Q4 | $17.2M | Buy |
457,659
+238,056
| +108% | +$8.74M | 0.05% | 456 |
|
|
2017
Q3 | $8M | Sell |
219,603
-102,126
| -32% | -$3.89M | 0.03% | 577 |
|
|
2017
Q2 | $12.7M | Sell |
321,729
-75,459
| -19% | -$2.75M | 0.05% | 460 |
|
|
2017
Q1 | $12.5M | Sell |
397,188
-1,026,360
| -72% | -$32.1M | 0.06% | 421 |
|
|
2016
Q4 | $44.5M | Buy |
1,423,548
+219,531
| +18% | +$7.11M | 0.24% | 112 |
|
|
2016
Q3 | $48.4M | Buy |
1,204,017
+705,738
| +142% | +$26.6M | 0.28% | 116 |
|
|
2016
Q2 | $16.6M | Buy |
498,279
+116,469
| +31% | +$3.98M | 0.11% | 255 |
|
|
2016
Q1 | $11.2M | Sell |
381,810
-433,671
| -53% | -$12M | 0.07% | 368 |
|
|
2015
Q4 | $21.5M | Sell |
815,481
-834,363
| -51% | -$21.7M | 0.15% | 194 |
|
|
2015
Q3 | $39.1M | Buy |
1,649,844
+1,559,844
| +1,733% | +$37.6M | 0.29% | 100 |
|
|
2015
Q2 | $2.14M | Buy |
+90,000
| New | +$2.03M | 0.01% | 727 |
|
|
2014
Q1 | – | Sell |
-84,162
| Closed | -$922K | – | 591 |
|
|
2013
Q4 | $922K | Sell |
84,162
-429,576
| -84% | -$4.84M | 0.01% | 446 |
|
|
2013
Q3 | $5.96M | Buy |
513,738
+163,992
| +47% | +$1.92M | 0.08% | 310 |
|
|
2013
Q2 | $3.92M | Buy |
+349,746
| New | +$4.14M | 0.07% | 351 |
|
Other funds holding EW
VCM
VPM
Balyasny Asset Management's EW Position: Q1 2026 in Review
Balyasny Asset Management reduced its Edwards Lifesciences (EW) stake by 99% in Q1 2026, selling an estimated $129M and leaving 9,998 shares worth $801K. The position accounts for ﹤0.01% of the portfolio, ranked #2166.
Balyasny Asset Management first reported a position in EW in Q2 2013 and has held it in 33 quarters since. The position peaked at $154M in Q1 2025. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Balyasny Asset Management held 9,998 shares of Edwards Lifesciences worth $801K as of Q1 2026.
- Balyasny Asset Management sold 1,564,393 Edwards Lifesciences shares in Q1 2026, an estimated $129M.
- Edwards Lifesciences made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2166 holding.
- Balyasny Asset Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 33 quarters since.
- Balyasny Asset Management's Edwards Lifesciences position peaked at $154M in Q1 2025.
- 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.